References: Overview of antipsychotic adverse effects

  • Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Rhythm Society. Circulation 2018;138(13):e272–e391. https://www.ncbi.nlm.nih.gov/pubmed/29084731
  • Beach SR, Celano CM, Sugrue AM, Adams C, Ackerman MJ, Noseworthy PA, et al. QT prolongation, torsades de pointes, and psychotropic medications: A 5-year update. Psychosomatics 2018;59(2):105–22. https://www.ncbi.nlm.nih.gov/pubmed/29275963
  • Cooper SJ, Reynolds GP, Barnes T, England E, Haddad PMWith expert c-a, et al. BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment. J Psychopharmacol 2016;30(8):717–48. https://www.ncbi.nlm.nih.gov/pubmed/27147592
  • Curtis J, Newall H, Samaras K. Positive cardiometabolic health: an early intervention framework for patients on psychotropic medication [fact sheet]. Sydney: NSW Government Health Education and Training (HETI); 2011. https://unsworks.unsw.edu.au/server/api/core/bitstreams/eb6d0621-bbf5-4229-afb4-1070d1bd9cb3/content
  • Curtis J, Newall HD, Samaras K. The heart of the matter: cardiometabolic care in youth with psychosis. Early Interv Psychiatry 2012;6(3):347–53. https://www.ncbi.nlm.nih.gov/pubmed/22221395
  • De Hert M, Detraux J, Stubbs B. Relationship between antipsychotic medication, serum prolactin levels and osteoporosis/osteoporotic fractures in patients with schizophrenia: a critical literature review. Expert Opin Drug Saf 2016;15(6):809–23. https://www.ncbi.nlm.nih.gov/pubmed/26986209
  • Eapen V, Shiers D, Curtis J. Bridging the gap from evidence to policy and practice: reducing the progression to metabolic syndrome for children and adolescents on antipsychotic medication. Aust N Z J Psychiatry 2013;47(5):435–42. https://www.ncbi.nlm.nih.gov/pubmed/23047958
  • Firth J, Siddiqi N, Koyanagi A, Siskind D, Rosenbaum S, Galletly C, et al. The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness. Lancet Psychiatry 2019;6(8):675–712. https://www.ncbi.nlm.nih.gov/pubmed/31324560
  • Galletly C, Castle D, Dark F, Humberstone V, Jablensky A, Killackey E, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Aust N Z J Psychiatry 2016;50(5):410–72. https://www.ncbi.nlm.nih.gov/pubmed/27106681
  • Galling B, Roldan A, Nielsen RE, Nielsen J, Gerhard T, Carbon M, et al. Type 2 diabetes mellitus in youth exposed to antipsychotics: A systematic review and meta-analysis. JAMA Psychiatry 2016;73(3):247–59. https://www.ncbi.nlm.nih.gov/pubmed/26792761
  • Grigg J, Worsley R, Thew C, Gurvich C, Thomas N, Kulkarni J. Antipsychotic-induced hyperprolactinemia: synthesis of world-wide guidelines and integrated recommendations for assessment, management and future research. Psychopharmacology (Berl) 2017;234(22):3279–97. https://www.ncbi.nlm.nih.gov/pubmed/28889207
  • Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry 2013;14(1):2–44. https://www.ncbi.nlm.nih.gov/pubmed/23216388
  • Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia - a short version for primary care. Int J Psychiatry Clin Pract 2017;21(2):82–90. https://www.ncbi.nlm.nih.gov/pubmed/28498090
  • Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry 2018;51(1-02):9–62. https://www.ncbi.nlm.nih.gov/pubmed/28910830
  • Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet 2019;394(10202):939–51. https://www.ncbi.nlm.nih.gov/pubmed/31303314
  • Lambert TJ, Reavley NJ, Jorm AF, Oakley Browne MA. Royal Australian and New Zealand College of Psychiatrists expert consensus statement for the treatment, management and monitoring of the physical health of people with an enduring psychotic illness. Aust N Z J Psychiatry 2017;51(4):322–37. https://www.ncbi.nlm.nih.gov/pubmed/28343435
  • Leucht S, Leucht C, Huhn M, Chaimani A, Mavridis D, Helfer B, et al. Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: Systematic review, bayesian meta-analysis, and meta-regression of efficacy predictors. Am J Psychiatry 2017;174(10):927–42. https://www.ncbi.nlm.nih.gov/pubmed/28541090
  • Mauri MC, Paletta S, Maffini M, Colasanti A, Dragogna F, Di Pace C, et al. Clinical pharmacology of atypical antipsychotics: an update. EXCLI J 2014;13:1163–91. https://www.ncbi.nlm.nih.gov/pubmed/26417330
  • National Institute for Health and Care Excellence (NICE). Psychosis and schizophrenia in adults: prevention and management [cg178]. London: NICE; 2014. https://www.nice.org.uk/guidance/cg178
  • National Prescribing Service (NPS). Antipsychotic monitoring tool. Sydney: NPS; 2011. https://resources.amh.net.au/public/antipsychotic-monitoring-tool.pdf
  • Ostuzzi G, Bighelli I, So R, Furukawa TA, Barbui C. Does formulation matter? A systematic review and meta-analysis of oral versus long-acting antipsychotic studies. Schizophr Res 2017;183:10–21. https://www.ncbi.nlm.nih.gov/pubmed/27866695
  • Pillinger T, McCutcheon RA, Vano L, Mizuno Y, Arumuham A, Hindley G, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry 2020;7(1):64–77. https://www.ncbi.nlm.nih.gov/pubmed/31860457
  • Polcwiartek C, Kragholm K, Schjerning O, Graff C, Nielsen J. Cardiovascular safety of antipsychotics: a clinical overview. Expert Opin Drug Saf 2016;15(5):679–88. https://www.ncbi.nlm.nih.gov/pubmed/26934282
  • Pringsheim T, Gardner D, Addington D, Martino D, Morgante F, Ricciardi L, et al. The assessment and treatment of antipsychotic-induced akathisia. Can J Psychiatry 2018;63(11):719–29. https://www.ncbi.nlm.nih.gov/pubmed/29685069
  • Priori SG, Blomstrom-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J 2015;36(41):2793–867. https://www.ncbi.nlm.nih.gov/pubmed/26320108
  • Schwartz PJ, Moss AJ, Vincent GM, Crampton RS. Diagnostic criteria for the long QT syndrome. An update. Circulation 1993;88(2):782–784 .https://www.ncbi.nlm.nih.gov/pubmed/8339437
  • Schwartz PJ, Woosley RL. Predicting the unpredictable: Drug-induced QT prolongation and torsades de pointes. J Am Coll Cardiol 2016;67(13):1639–50. https://www.ncbi.nlm.nih.gov/pubmed/27150690
  • Schneider-Thoma J, Chalkou K, Dorries C, Bighelli I, Ceraso A, Huhn M, et al. Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis. Lancet 2022;399(10327):824-36. https://www.ncbi.nlm.nih.gov/pubmed/35219395
  • Solmi M, Murru A, Pacchiarotti I, Undurraga J, Veronese N, Fornaro M, et al. Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. Ther Clin Risk Manag 2017;13:757–77. https://www.ncbi.nlm.nih.gov/pubmed/28721057
  • Stroup TS, Gray N. Management of common adverse effects of antipsychotic medications. World Psychiatry 2018;17(3):341–56. https://www.ncbi.nlm.nih.gov/pubmed/30192094
  • Taylor D, Barnes TRE, Young AH. The Maudsley prescribing guidelines in psychiatry. 13th Oxford: Wiley-Blackwell; 2018. https://onlinelibrary.wiley.com/doi/book/10.1002/9781119870203?msockid=1a22d7ae00166d6324eec41701066cec
  • Taylor D, Paton C, Kapur S. The Maudsley prescribing guidelines in psychiatry. 11th Oxford: Wiley-Blackwell; 2012.
  • Tisdale JE, Jaynes HA, Kingery JR, Mourad NA, Trujillo TN, Overholser BR, et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes 2013;6(4):479–87. https://www.ncbi.nlm.nih.gov/pubmed/23716032
  • Vancampfort D, Stubbs B, Mitchell AJ, De Hert M, Wampers M, Ward PB, et al. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. World Psychiatry 2015;14(3):339–47. https://www.ncbi.nlm.nih.gov/pubmed/26407790